APA (7th ed.) Citation

RM, G., JD, G., P, M., SD, P., VC, W., & JA, L. (2024). Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(3), e13663. https://doi.org/10.1111/obr.13663

Chicago Style (17th ed.) Citation

RM, Goldenberg, Gilbert JD, Manjoo P, Pedersen SD, Woo VC, and Lovshin JA. "Management of Type 2 Diabetes, Obesity, or Nonalcoholic Steatohepatitis with High-dose GLP-1 Receptor Agonists and GLP-1 Receptor-based Co-agonists." Obesity Reviews : An Official Journal of the International Association for the Study of Obesity 25, no. 3 (2024): e13663. https://doi.org/10.1111/obr.13663.

MLA (9th ed.) Citation

RM, Goldenberg, et al. "Management of Type 2 Diabetes, Obesity, or Nonalcoholic Steatohepatitis with High-dose GLP-1 Receptor Agonists and GLP-1 Receptor-based Co-agonists." Obesity Reviews : An Official Journal of the International Association for the Study of Obesity, vol. 25, no. 3, 2024, p. e13663, https://doi.org/10.1111/obr.13663.